Results 131 to 140 of about 10,090 (144)

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul E Sax, Anton L Pozniak, Andrea Antinori   +2 more
exaly  

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Lancet HIV,the, 2020
Simiso Sokhela, Bryony Simmons, Michelle A Moorhouse   +2 more
exaly  

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Lancet, The, 2019
Andrea Antinori, Chien-Ching Hung, Michael Aboud   +2 more
exaly  

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Lancet, The, 2014
Bonaventura Clotet, Judith Feinberg, Andrea Antinori   +2 more
exaly  

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Lancet, The, 2017
Adriano Lazzarin, Chloe Orkin, Daniel Podzamczer   +2 more
exaly  

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

New England Journal of Medicine, 2019
Willem Venter, Michelle A Moorhouse, Simiso Sokhela   +2 more
exaly  

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

New England Journal of Medicine, 2013
Sharon L Walmsley, Felix Gutierrez, Franco Maggiolo   +2 more
exaly  

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

New England Journal of Medicine, 2019
Sandrine Leroy, Sylvie Boyer, Alexandra Calmy   +2 more
exaly  

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Lancet Infectious Diseases, The, 2019
Richard Kaplan, Fujie Zhang, Ploenchan Chetchotisak   +2 more
exaly  

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Lancet Infectious Diseases, The, 2012
Franco Maggiolo, Jose R Arribas, Benjamin Young   +2 more
exaly